Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.…
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Meta-analysis of GEO datasets identifies specific gene expression alterations in aflatoxin-associated intrahepatic cholangiocarcinoma.
Could aflatoxin exposure change specific genes in liver cancer, and what does that mean for prevention?
This meta-analysis examined genomic data from five Gene Expression Omnibus datasets to identify expression patterns in aflatoxin-induced int…
Liver cancer linked to aflatoxin exposure changes six specific genes, revealing new genetic pathways that could help doctors find early warn…